3-(4-Hydroxy-3,5-diiodophenyl)pentanoic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-(4-Hydroxy-3,5-diiodophenyl)pentanoic acid
• 化学式: C₁₁H₁₂I₂O₃
• 分子量: 446.02
• InChiKey: OHPBHVLUNAGFMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
  申请人：Arizona Board of Regents on Behalf of The University of Arizona

  公开号：US20020151594A1

  公开（公告）日：2002-10-17

  Applicants' invention includes a method to treat a patient having congestive heart failure by administering a therapeutically effective amount of 3,5-diidothyropropionic acid. Applicants' invention further includes a method to lower cholesterol blood levels of a patient by administering a therapeutically effective amount of 3,5-diidothyropropionic acid. Applicants' invention further includes a synthetic method to prepare 3,5-diidothyropropionic acid.

  申请人的发明包括一种通过给予治疗有效量的3,5-二碘甲状腺酸来治疗充血性心力衰竭患者的方法。申请人的发明还包括一种通过给予治疗有效量的3,5-二碘甲状腺酸来降低患者胆固醇血液水平的方法。申请人的发明还包括一种合成3,5-二碘甲状腺酸的方法。
• METHOD TO TREAT CHRONIC HEART FAILURE AND/OR ELEVATED CHOLESTEROL LEVELS USING 3,5-DIIODOTHYROPROPIONIC ACID AND METHOD TO PREPARE SAME
  申请人：The Arizona Board of Regents on Behalf of the University of Arizona

  公开号：EP1432310A2

  公开（公告）日：2004-06-30
• EP1432310A4
  申请人：——

  公开号：EP1432310A4

  公开（公告）日：2006-06-21
• Method for stimulating weight loss and/or for lowering triglycerides in patients
  申请人：Morkin Eugene

  公开号：US20080146668A1

  公开（公告）日：2008-06-19

  Administration of a therapeutically effective amount of 3,5-diiodothyropropionic acid stimulates weight loss in patients, lowers triglyceride levels and reduces risk of death or progression of coronary heart disease in patients with metabolic syndrome.
• METHOD FOR STIMULATING WEIGHT LOSS AND/OR FOR LOWERING TRIGLYCERIDES IN PATIENTS
  申请人：MORKIN Eugene

  公开号：US20090076151A1

  公开（公告）日：2009-03-19

  Administration of a therapeutically effective amount of 3,5-diiodothyropropionic acid stimulates weight loss in patients, lowers triglyceride levels and reduces risk of death or progression of coronary heart disease in patients with metabolic syndrome.